OptiNose, Inc. [OPTN], a pharmaceutical company specializing in innovative drug delivery solutions, announced its financial results for the third quarter of 2023. The company reported a net loss of $9.3 million and generated $19.8 million in revenue during the quarter, covering the period from July 1 to September 30, 2023.
Despite the net loss, OptiNose achieved a 1% decrease in revenue compared to the same quarter in the previous year. The company's operating loss for the quarter amounted to $1.7 million. Depreciation and amortization expenses accounted for $0.3 million, while stock-based compensation reached $4.2 million. Additionally, changes in fair value of the warrant liability resulted in a $3.2 million unrealized gain, reflecting the volatility of financial markets.
During the first nine months of 2023, OptiNose recorded total revenues of $51.1 million, representing a slight decline of 7% compared to the same period in 2022. The decline can be attributed to a decrease in sales volume, partially offset by favorable pricing dynamics. The cost of product sales amounted to $6.5 million, resulting in a gross profit of $44.6 million.
OptiNose maintained a stable financial position during the third quarter of 2023 with total assets of $101.4 million. The company's liabilities amounted to $179 million, leading to a stockholders' deficit of $77.6 million. With $66.8 million in cash and cash equivalents, OptiNose remains well-positioned to support its ongoing operations.
OptiNose reported basic and diluted losses per share of $0.08 for the third quarter of 2023. With 112.2 million shares outstanding, both on a basic and diluted basis, the company aims to improve its financial performance and generate value for its shareholders in the upcoming quarters.
Looking ahead, OptiNose remains focused on expanding its product portfolio and enhancing its drug delivery platforms. The company plans to advance its pipeline of innovative medications, leveraging its patented Exhalation Delivery Systems (EDS). OptiNose aims to address unmet medical needs and capitalize on the growing demand for patient-friendly treatment options.
Despite a net loss in the third quarter, OptiNose demonstrated resilience in its financial performance. The company's revenue trajectory remained steady, and it continues to invest in research and development efforts to drive future growth. With a strong cash position and a strategic focus on innovation, OptiNose is well-positioned for long-term success in the pharmaceutical industry.